ArticleiScience2021
Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease.
Open access · goldAbstract read
In one paragraph
Article in iScience, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- The fatty liver index exhibits a dual association with chronic obstructive pulmonary disease: a machine learning-based analysis of two independent cohorts.Frontiers in nutrition · 2026Article
- Loss of LCAT function aggravates metabolic-associated steatohepatitis (MASH) in golden Syrian hamster.Clinical science (London, England : 1979) · 2025Article
- AAV8-mediated silencing of Atad3 prevents the progression from simple steatosis to MASH in mice by reduced IL6 secretion.Biochimica et biophysica acta. Molecular basis of disease · 2025Article
- Tspo Depletion Exacerbates Steatosis Through Fatty Acid Uptake.Journal of cellular and molecular medicine · 2025Article
- The mitochondrial TSPO ligand Atriol mitigates metabolic-associated steatohepatitis by downregulating CXCL1.Metabolism: clinical and experimental · 2024Article
- Application of TSPO-Specific Positron Emission Tomography Radiotracer as an Early Indicator of Acute Liver Failure Induced by Propacetamol, a Prodrug of Paracetamol.International journal of molecular sciences · 2024Article
- Regulation of astrocyte metabolism by mitochondrial translocator protein 18kDa.bioRxiv : the preprint server for biology · 2023Article
- Mitochondria in endothelial cells angiogenesis and function: current understanding and future perspectives.Journal of translational medicine · 2023Review
- Mitochondrial TSPO Promotes Hepatocellular Carcinoma Progression through Ferroptosis Inhibition and Immune Evasion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Impact of Fetal Exposure to Endocrine Disrupting Chemical Mixtures on FOXA3 Gene and Protein Expression in Adult Rat Testes.International journal of molecular sciences · 2023Article
- Translocator protein in the rise and fall of central nervous system neurons.Frontiers in cellular neuroscience · 2023Review
- Effects of various interventions on non-alcoholic fatty liver disease (NAFLD): A systematic review and network meta-analysis.Frontiers in pharmacology · 2023Review
- Chromosome-level genome and population genomics reveal evolutionary characteristics and conservation status of Chinese indigenous geese.Communications biology · 2022Article
- MicroRNA-379-5p regulates free cholesterol accumulation and relieves diet induced-liver damage in db/db mice via STAT1/HMGCS1 axis.Molecular biomedicine · 2022Article
- Loss of mitochondrial ATPase ATAD3A contributes to nonalcoholic fatty liver disease through accumulation of lipids and damaged mitochondria.The Journal of biological chemistry · 2022Article
- Feasibility of TSPO-Specific Positron Emission Tomography Radiotracer for Evaluating Paracetamol-Induced Liver Injury.Diagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors at 3 institutions in 3 countries.
Yuchang LiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Liting ChenDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Lu LiDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Chantal SottasDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Stephanie K PetrilloResearch Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Anthoula LazarisResearch Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Peter MetrakosResearch Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Hangyu WuDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Yuji IshidaDepartment of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Takeshi SaitoDepartment of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Lucy Golden-MasonDepartment of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Hugo R RosenDepartment of Medicine, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, CA 90089, USA.
Jeremy J WolffBruker Daltonics, 40 Manning Road Billerica, MA 01821, USA.
Cristina I SilvescuBruker Daltonics, 40 Manning Road Billerica, MA 01821, USA.
Samuel GarzaDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Garett CheungDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Tiffany HuangDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Jinjiang FanResearch Institute of the McGill University Health Center, Montreal, QC H4A 3J1, Canada.
Martine CultyDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Bangyan StilesDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
Kinji AsahinaUniversity of Southern California Research Center for Liver Diseases, Los Angeles, CA 90089, USA.
Vassilios PapadopoulosDepartment of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA 90089, USA.
University of Southern California · USMcGill University Health Centre · CABruker (United States) · US
Funding
USC RESEARCH CENTER FOR LIVER DISEASES: PILOT PROGRAMSP30DK048522 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI KAPLOWITZ, NEIL · 1995 to 2020
$21.8MInnate Defense Program against HCVR01DK101773 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAITO, TAKESHI · 2015 to 2019
$1.9MHuman Group 2 Innate Lympohocyte Cell (ILC2) populations contribute to Hepatic FibrosisR01DK106491 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOLDEN, LUCY MARY · 2015 to 2019
$1.8MInnate Immunity, Cholesterol, and NASH PathogenesisR01DK117004 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI GOLDEN, LUCY MARY · 2020 to 2023
$1.5MImpact of Occult Hepatitis C Virus Infection in Progression of Liver DiseasesR21AI139954 · NIAID · UNIVERSITY OF SOUTHERN CALIFORNIA · PI SAITO, TAKESHI · 2018 to 2019
$454kRoles of lysophosphatidic acid in alcoholic liver diseaseR21AA027222 · NIAAA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ASAHINA, KINJI · 2019 to 2020
$433kNIAAA NIH HHS R21 AA027222NIAID NIH HHS R21 AI139954NIDDK NIH HHS P30 DK048522NIDDK NIH HHS R01 DK101773NIDDK NIH HHS R01 DK106491NIDDK NIH HHS R01 DK117004
Abstract
Translocator protein (TSPO, 18 kDa) levels increase in parallel with the evolution of simple steatosis (SS) to nonalcoholic steatohepatitis (NASH) in nonalcoholic fatty liver disease (NAFLD). However, TSPO function in SS and NASH is unknown. Loss of TSPO in hepatocytes
Indexed as
Cell biologyMetabolomicsMolecular biology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.